29 August 2019

Flagging notification in Scandion Oncology A/S

Attachments Download report
Scandion Oncology A/S (”Scandion Oncology”) hereby announces that, in connection with the registration of the new share issue carried out during the second quarter 2019, the main shareholders ownership in Scandion Oncology has decreased.

Saniona AB previously owned approx. 29.17 percent of the shares in Scandion Oncology. In connection with the new share issue, Saniona AB's ownership decreased to approx. 18.23 percent of the shareholding in Scandion Oncology.

CSO and co-founder Jan Stenvang's holdings decreased in connection with the new share issue from approx. 11.94 percent to approx. 7.46 percent of the shareholding in Scandion Oncology.

For further information regarding Scandion Oncology, please contact:

Nils Brünner, CEO

Phone: +45 26 14 47 08

E-mail: nb@scandiononcology.com

Scandion Oncology A/S is a biotechnology company founded in 2017 for the purpose of addressing and tackling one of the greatest challenges in modern oncology – the effective treatment of cancer which contains drug resistant cells or which has developed resistance to a previously prescribed cancer-fighting drug. In preclinical in vitro-studies SCO-101 restores chemotherapy sensitivity in resistant patient-derived cancer cells. Moreover, in animal studies, the company’s leading candidate drug, SCO-101, significantly enhances the efficacy of certain standard cancer treatments when given in combination. Scandion Oncology is now ready to initiate clinical phase II trials with its lead compound, SCO-101 in patients with drug resistant cancer. Scandion Oncology was listed on Spotlight Stock Market, Sweden in November 2018.

Attachments Download report